New Product Launched: Cytidine and Uridine

Haorui is launching two new products: Cytidine and Uridine, the two are nucleotides, which are recently reported as the starting materials to manufacture MERCK's promising devloping COVID-19 new drug-Molnupiravir（MK-4482）

On January 25, 2021, Merck stated Molnupiravir is currently being evaluated in Phase 2/3 clinical trials in both the hospital and out-patient settings. The primary completion date for the Phase 2/3 studies is May 2021. The company anticipates initial efficacy data in the first quarter of 2021, which Merck plans to share publicly if clinically meaningful.

We have plenty stock of Cytidine and Uridine, if you're interested in them, kindly turn to us by info@haorui.com.